Profile data is unavailable for this security.
About the company
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
- Revenue in USD (TTM)376.07m
- Net income in USD-16.14m
- Incorporated2016
- Employees354.00
- LocationArcutis Biotherapeutics Inc3027 Townsgate Road, Suite 300WESTLAKE VILLAGE 91361United StatesUSA
- Phone+1 (805) 418-5006
- Fax+1 (302) 636-5454
- Websitehttps://arcutis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phibro Animal Health Corp | 1.46bn | 92.09m | 2.12bn | 2.48k | 23.17 | 6.37 | 14.83 | 1.45 | 2.26 | 2.26 | 35.88 | 8.21 | 1.09 | 2.09 | 7.18 | 591,646.40 | 6.84 | 3.89 | 8.47 | 4.87 | 32.56 | 31.14 | 6.29 | 3.69 | 1.22 | 4.39 | 0.6875 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
| Ultragenyx Pharmaceutical Inc | 673.00m | -575.00m | 2.13bn | 1.37k | -- | -- | -- | 3.17 | -5.83 | -5.83 | 6.83 | -0.8282 | 0.4434 | 2.25 | 4.81 | 490,882.60 | -37.89 | -37.78 | -50.15 | -45.91 | 83.80 | 88.44 | -85.44 | -122.25 | 2.34 | -14.66 | 1.07 | -- | 20.13 | 19.95 | -1.02 | -- | -13.71 | -- |
| Ocular Therapeutix Inc | 51.95m | -265.94m | 2.34bn | 325.00 | -- | 3.55 | -- | 45.09 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
| Apellis Pharmaceuticals Inc | 1.00bn | 22.39m | 2.58bn | 733.00 | 163.27 | 6.90 | 107.62 | 2.57 | 0.1235 | 0.1235 | 7.90 | 2.92 | 1.02 | 0.913 | 3.18 | 1,369,416.00 | 2.28 | -48.52 | 3.09 | -62.30 | 89.81 | 87.55 | 2.23 | -90.49 | 2.70 | 1.78 | 0.5516 | -- | 28.46 | 31.98 | 111.31 | -- | -43.47 | -- |
| Liquidia Corp | 69.22m | -121.85m | 2.76bn | 157.00 | -- | 125.12 | -- | 39.94 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
| Twist Bioscience Corp | 391.56m | -76.58m | 2.86bn | 979.00 | -- | 6.27 | -- | 7.30 | -1.27 | -1.27 | 6.46 | 7.44 | 0.6282 | 6.71 | 8.76 | 399,956.10 | -12.29 | -24.09 | -13.97 | -26.80 | 51.62 | 43.29 | -19.56 | -67.76 | 3.37 | -- | 0.00 | -- | 20.32 | 33.11 | 62.79 | -- | 23.20 | -- |
| Catalyst Pharmaceuticals Inc | 588.99m | 214.33m | 2.92bn | 182.00 | 14.20 | 3.07 | 11.58 | 4.96 | 1.68 | 1.68 | 4.63 | 7.79 | 0.6024 | 3.08 | 6.14 | 3,236,203.00 | 21.92 | 22.15 | 25.40 | 25.81 | 85.19 | 85.59 | 36.39 | 31.20 | 5.82 | -- | 0.00 | 0.00 | 19.78 | 37.68 | 30.78 | 23.37 | 38.45 | -- |
| Arcutis Biotherapeutics Inc | 376.07m | -16.14m | 2.93bn | 354.00 | -- | 15.36 | -- | 7.78 | -0.1325 | -0.1325 | 2.93 | 1.54 | 0.962 | 1.97 | 3.43 | 1,062,350.00 | -4.13 | -48.93 | -5.65 | -57.14 | 90.24 | -- | -4.29 | -147.21 | 2.99 | -3.84 | 0.3651 | -- | 91.34 | -- | 88.47 | -- | 101.59 | -- |
| Supernus Pharmaceuticals Inc | 718.95m | -38.55m | 3.14bn | 674.00 | -- | 2.95 | 59.14 | 4.37 | -0.6839 | -0.6839 | 12.70 | 18.48 | 0.5098 | 1.09 | 4.36 | -- | -2.73 | 2.01 | -3.52 | 2.67 | 89.63 | 87.96 | -5.36 | 4.66 | 1.66 | -- | -- | -- | 8.63 | 6.68 | -152.19 | -- | -- | -- |
| Tarsus Pharmaceuticals Inc | 451.36m | -66.42m | 3.26bn | 370.00 | -- | 9.49 | -- | 7.22 | -1.61 | -1.61 | 10.81 | 8.07 | 0.9612 | 8.78 | 6.85 | 1,219,892.00 | -14.14 | -27.80 | -18.38 | -32.78 | 93.20 | 93.45 | -14.72 | -53.60 | 3.82 | -- | 0.1742 | -- | 146.71 | -- | 42.52 | -- | 84.92 | -- |
| Prestige Consumer Healthcare Inc | 1.10bn | 186.50m | 3.26bn | 600.00 | 18.25 | 1.78 | 15.07 | 2.96 | 3.78 | 3.78 | 22.38 | 38.66 | 0.3234 | 3.07 | 6.17 | 1,839,343.00 | 5.47 | 4.13 | 5.67 | 4.30 | 56.12 | 56.31 | 16.90 | 13.13 | 1.93 | 8.28 | 0.3657 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 677.56m | 59.01m | 3.47bn | 366.00 | 60.92 | 6.10 | 57.34 | 5.12 | 0.7448 | 0.7448 | 8.58 | 7.44 | 1.01 | 1.91 | 23.64 | 1,851,268.00 | 8.78 | 2.35 | 10.69 | 2.75 | 88.54 | 87.48 | 8.71 | 3.40 | 3.39 | -- | 0.00 | 0.00 | 60.09 | -- | 236.61 | -- | 40.84 | -- |
| Corcept Therapeutics Inc | 761.41m | 99.65m | 3.75bn | 730.00 | 42.49 | 5.77 | 37.23 | 4.93 | 0.8303 | 0.8303 | 6.35 | 6.11 | 0.908 | 1.03 | 13.39 | 1,043,023.00 | 11.88 | 17.68 | 14.54 | 20.76 | 98.30 | 98.47 | 13.09 | 20.88 | 2.85 | -- | 0.00 | 0.00 | 12.79 | 16.56 | -29.43 | -1.23 | -29.80 | -- |
Data as of Mar 03 2026. Currency figures normalised to Arcutis Biotherapeutics Inc's reporting currency: US Dollar USD
52.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Suvretta Capital Management LLCas of 31 Dec 2025 | 11.96m | 9.77% |
| Rubric Capital Management LPas of 31 Dec 2025 | 8.27m | 6.75% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 7.99m | 6.52% |
| Jennison Associates LLCas of 31 Dec 2025 | 6.76m | 5.52% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 6.35m | 5.18% |
| Polar Capital LLPas of 31 Dec 2025 | 5.56m | 4.54% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 5.49m | 4.48% |
| Gilder, Gagnon, Howe & Co. LLCas of 31 Dec 2025 | 4.45m | 3.64% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 4.02m | 3.29% |
| UBS Securities LLCas of 31 Dec 2025 | 3.23m | 2.64% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
